Patient-based strategy for systemic treatment of metastatic renal cell carcinoma.
There were only a few options 3 years ago to treat metastatic renal cell carcinoma (mRCC), a disease with a very poor prognosis. With the approval of targeted therapies for mRCC since December 2005, this situation has changed dramatically. Currently, oncologists can choose between several promising options to improve the longevity and quality of their patients' lives. A widely accepted treatment scheme for targeted therapies in mRCC does not yet exist. Based on a selective literature search, drawing on studies with six targeted therapies for mRCC, and including data from the latest American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) Annual Meetings, this review introduces the available therapies, evaluates patient-specific criteria for their application and suggests an algorithm for a patient-based treatment scheme. Clinical experiences with sequential therapies are summarized and potential combination therapies discussed. In conclusion, the crucial criteria of the treatment scheme we propose are the tumor burden and the disease pace, as well as the quality of life of a patient. These define whether tumor control or tumor remission should be the primary therapeutic goal. This scheme suggests which kind of therapeutic sequence to pursue to optimize patient care in mRCC.
Kirchner
Hartmut
H
Klinikum Region Hannover GmbH, Krankenhaus Siloah, Medizinische Klinik III, Roesebeckstr 15, 30449 Hannover, Germany. hartmut.kirchner@krh.eu
Strumberg
Dirk
D
Bahl
Amit
A
Overkamp
Friedrich
F
D000465:Algorithms; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000628:therapy*; D016503:Drug Delivery Systems; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D009362:Neoplasm Metastasis; D057285:Precision Medicine / Q000379:methods; D011379:Prognosis; D011788:Quality of Life; D012074:Remission Induction / Q000379:methods; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects